Antibe Therapeutics Inc(Pre-Merger) ATBPF

To do list ... IMO

[MrMugsy]

To Do List (2022 and 2023) ...

1.  IBD update (before Christmas 2022)
2.  Animal Studies (late 2022 or early 2023) - assume little is shared here
3.  IND studies begin for IBD - 2023
4.  IND studies begin for another drug (very high pain(IV) ??? unless 346 works) - 2023
5.  PK Study for OTENA - H1 2023 (March ?)
6.  P2 Acute trial begins - H1 2023 (April ?)
7.  P2 Acute trial readout - H2 2023
8.  Negotiations to start - H2 2023

[WalterWheat21]

How soon do you think we'll hear about the patent approval for the amorphous formulation?

[StockingUp21]

average time 2 or 3 years  

[WalterWheat21]

Please don't respond back to me. You are the lowest *** and no one here wants to hear from you, or the other 2 goons.

[StockingUp21]

not surprised you were not looking for honest answer

[MrMugsy]

Hahaha - interesting. This is a very good place for some to really think about what this investment is ... In drug development, there is a lot of development work done in secrecy - it has to be that way. You can't show your cards early. You don't want to give away too much information. You want it to be extremely difficult to reporduce your work - OR - even to understand your work. Yet -

[yureja85]

This post has been removed in accordance with Community Policy

[MrMugsy]

I don't think we will get any additional information on the IP. If I understand ... they now have one year to fortify their position with that IP ... to make it stronger. Likely tight lipped. Focus on animal studies and P2 right now - along with an IP for IBD and then an IBD update.